All News
Filter News
Found 808,896 articles
-
New Immunomodulatory Therapeutic Vaccine that Targets Oligomeric Amyloid-β Could be Step Towards Halting Alzheimer’s Disease Progression
10/27/2020
Alzheimer’s disease affects more than 5.8 million Americans at an estimated cost at over $305 billion in 2020 according to the Alzheimer's Association.
-
Quest Diagnostics and Catapult Health Provide Virtual Preventive Care Services for Employers During COVID-19 Pandemic and Beyond
10/27/2020
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and Catapult Health, the leading national provider of employer-sponsored Preventive Checkups, have formed a collaboration designed to help organizations facilitate virtual (telehealth) access to clinical services for their employees and adult dependents,
-
Managed Access innovator RareiTi appoints Dr. Olivia Kessel as Chief Medical Officer
10/27/2020
Technology enabled, data-driven Managed Access company RareiTi is delighted to announce the appointment of Dr. Olivia Kessel as Chief Medical Officer.
-
Mitsubishi Tanabe Pharma America Celebrates ALS Caregiver & Screenwriter Featured In MDA Kevin Hart Kids Telethon
10/27/2020
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that Aleia Kristene Asbey , aspiring screenwriter and participant in the ALSO US ™ caregiver program for teen
-
Bausch + Lomb Introduces SimplifEYE™ IOL Delivery System For enVista® Toric And Monofocal Preloaded Intraocular Lenses
10/27/2020
First Preloaded Toric Available in the United States and Monofocal Option Combine Consistent IOL Delivery with Outstanding Visual Outcomes of enVista®
-
Vidence and 2bPrecise Announce Strategic Partnership to Unleash the Power of Genomic Data in Precision Oncology
10/27/2020
Vidence, an oncology informatics company, has selected the 2bPrecise™ platform, a precision medicine data delivery solution, to make it easier for its Consortium Fellows to unlock the true power of genomic data at the point of care and facilitate the advancement of precision oncology
-
Prilenia Enrolls First Patients Into its PROOF-HD Phase 3 Clinical Trial for Huntington’s Disease in the United States
10/27/2020
PROOF-HD is designed to replicate previous findings of pridopidine demonstrating maintenance of functional capacity in early Huntington’s Disease patients
-
ImmunoPrecise and Twist Bioscience Announce Collaboration for the Creation of Novel, Therapeutic Products
10/27/2020
IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSXV: IPA) (OTCQB: IPATF) (FSE:TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced that its subsidiary, Talem Therapeutics, entered into a collaboration with Twist Bioscience Corporation (NASDAQ: TWST),
-
New Study Shows 34% Reduction in Dengue, Zika Transmission with Innovative SC Johnson Spatial Repellent
10/27/2020
A spatial repellent product designed by SC Johnson could reduce dengue and Zika infections by an estimated 34%, according to new research released by the University of Notre Dame.
-
Olatec Therapeutics Enrolls its First Patients in a Phase 2 Clinical Trial in COVID-19 with its Selective NLRP3 Inhibitor, Oral Dapansutrile
10/27/2020
Olatec Therapeutics LLC announced today that patients are being enrolled in a trial described as: “A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Orally Administered Dapansutrile Capsules for the Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome.”
-
Taysha Gene Therapies Receives Rare Pediatric Disease Designation and Orphan Drug Designation for TSHA-104 to Treat SURF1-Associated Leigh Syndrome
10/27/2020
Rare pediatric disease and orphan drug designations now obtained in multiple pipeline programs, including TSHA-101 for GM2 gangliosidosis, TSHA-102 for Rett syndrome and TSHA-118 for CLN1
-
Soliton Appoints Dr. Michael Kaminer to Board of Directors
10/27/2020
Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary aesthetic platform technology, today announced it has appointed Michael S. Kaminer, M.D. to Soliton's Board of Directors.
-
TAE Life Sciences and CNAO (National Center of Oncological Hadrontherapy) Announce a Research and Clinical Collaboration for the Implementation of a New Facility with Boron Neutron Capture Therapy System in Italy
10/27/2020
TAE Life Sciences, a biologically-targeted radiation therapy company developing a breakthrough, accelerator-based boron neutron capture therapy system, announced that it has entered into an agreement with National Center of Oncological Hadrontherapy to provide its Alphabeam™ Neutron System for the treatment of invasive, recurrent and difficult to treat cancers.
-
Takeda Presents Rare Bleeding Disorders Research at Thrombosis & Hemostasis Summit of North America (THSNA) 2020
10/27/2020
Takeda Pharmaceutical Company Limited ( TSE: 4502/NYSE:TAK ) (“Takeda”), today presented four abstracts at the Thrombosis and Hemostasis Summit of North America (THSNA), highlighting Takeda’s commitment to advancing personalized care in people living with bleeding disorders. These studies may help provide further data to healthcare providers regarding treatment personalization in patients with he
-
aTyr Pharma to Participate in ROTH Capital Partners Webinar on COVID-19 Therapeutics in Development on October 28th
10/27/2020
aTyr Pharma, Inc. announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will participate in a panel titled, “Immune Modulators to Ameliorate COVID-19” as part of the ROTH Capital Partners Webinar on COVID-19 Therapeutics in Development on October 28, 2020.
-
Preclinical Study of Neumentix™ Illuminates Mechanism of Action in the Natural Antioxidant for Cognitive Performance
10/27/2020
Kemin Industries, a global ingredient manufacturer that strives to sustainably transform the quality of life every day for 80 percent of the world with its products and services, announced today new preclinical research that expands the scientific understanding of the mechanism of action of Neumentix™,
-
Inscripta Appoints Sri Kosaraju as President and CEO
10/27/2020
Inscripta, Inc., the digital genome engineering company, today announced the appointment of Sri Kosaraju as President and CEO
-
Strata Oncology Announces Medicare Coverage of StrataNGS Comprehensive Genomic Profiling Test for Patients with Advanced Solid Tumors
10/27/2020
Strata Oncology, Inc ., a precision oncology company advancing molecular indications for cancer therapies, today announced that Palmetto GBA , a Medicare Administrative Contractor (MAC), has established coverage
-
Kala Pharmaceuticals Announces FDA Approval of EYSUVIS™ for the Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease
10/27/2020
Kala Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, announced that the U.S. Food and Drug Administration has approved EYSUVIS 0.25% for the short-term treatment of the signs and symptoms of dry eye disease.
-
Scholar Rock Announces Positive Proof-of-Concept Data from TOPAZ Phase 2 Trial Interim Analysis of SRK-015 in Patients with Type 2 and Type 3 Spinal Muscular Atrophy
10/27/2020
Motor function improvements were observed for all three SRK-015 treatment cohorts in the primary efficacy endpoints (Hammersmith scale scores) at six-months; top-line data from the 12-month treatment period are anticipated in 2Q21